Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.

CONCLUSION: This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.
PMID: 31040252 [PubMed - as supplied by publisher]

Source: The Oncologist - April 29, 2019 Category: Cancer & Oncology Authors: Chihara Y, Yoshimura A, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Takeuchi M, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K Tags: Oncologist Source Type: research